Metraipolis › archive › dc_f9214190aeed
Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide in patients with chronic kidney disease — Europe PMC PMID:41160422
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41160422
- DOI
- 10.1093/ndt/gfaf230
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-02T22:58:56.695Z
- SHA-256 of the archived text
3eb4c81de7cefd2053c9c9ab165f45413ded25641b5bc86895bf34292f952305- Stable URL of this page
https://metraipolis.com/documento/dc_f9214190aeed
How to cite
Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide in patients with chronic kidney disease — Europe PMC PMID:41160422 — Europe PMC (en), https://europepmc.org/article/MED/41160422 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_f9214190aeed (Metraipolis archive dc_f9214190aeed, sha256 3eb4c81de7cefd2053c9c9ab165f45413ded25641b5bc86895bf34292f952305)
BibTeX
@misc{dcf9214190aeed,
title = {Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide in patients with chronic kidney disease — Europe PMC PMID:41160422},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41160422},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_f9214190aeed; sha256 3eb4c81de7cefd2053c9c9ab165f45413ded25641b5bc86895bf34292f952305},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41160422. Agents can read the archived copy with the MCP tool read_document.